Sign in
TerminatedPhase 1/2

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

Key facts

Who runs it
University of Washington
Where
Seattle, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1/2
People taking part
8 people enrolled
Started
17 Apr 2024
Ended
26 Sept 2025
Type of study
Interventional
Treatments tested
  • Near Infrared Imaging
  • Therapeutic Conventional Surgery
  • Tozuleristide
Record updated
16 September 2026
Why it stopped
Terminated due to suboptimal delineation of fluorescence between tumor and native oral cavity mucosa.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (16)Hide the full registry criteria

Who can take part

  • Adult subjects age >= 18 years (yr)
  • Subjects must have suspected or confirmed oral cavity dysplasia or cT1-4 squamous cell carcinoma for which surgical excision is deemed clinically indicated by the treating physician. Histology confirmation not required prior to surgery
  • Able to provide written informed consent
  • If of child-bearing potential, agree to the continued use of 2 reliable forms of contraception from study enrollment through 30 days after receiving the study product. Male subjects must agree to use 2 reliable methods of contraception simultaneously for 30 days after receiving the study product if their partner is of child-bearing potential
  • Available for all study visits and able to comply with all study requirements

Who cannot take part

  • In the opinion of the treating physician, subject has received photosensitizing medication that could interfere or confound study results
  • Any current medications with the potential to generate fluorescence or photochemical reaction
  • Positive pregnancy test or planning to become pregnant within 30 days (d) of receiving tozuleristide
  • Any current condition, including psychological and social situations which, in the opinion of the investigator, would impact adversely on the subject or the interpretation of the study data
  • Creatinine clearance < 60 mL/min
  • Aspartate aminotransferase (AST) > 1.5 x upper limit of normal (ULN)
  • Alanine aminotransferase (ALT) > 1.5 x ULN
  • Bilirubin > 1.5 x ULN
  • Known or suspected sensitivity to indocyanine green
  • Enrolled in any other ongoing study
  • Currently lactating or breastfeeding

Where in United States

  • Fred Hutch/University of Washington Cancer ConsortiumSeattle, United States

About the trial

What the trial wants to find out

This phase I/II trial studies the side effects of tozuleristide in imaging oral cavity squamous cell cancer and high-grade oral cavity dysplasia during surgery. Tozuleristide is an imaging agent that specifically binds to tumor cells. When exposed to near-infrared light, tozuleristide causes tumor cells to fluoresce (light up), so that surgeons may better distinguish tumor cells from healthy cells during surgery.

The group in the trial

  • Diagnostic (tozuleristide, surgery, NIR imaging)Treatment being tested

    Beginning 1 hour before surgery, patients receive tozuleristide intravenously (IV) over 1-5 minutes. Patients then surgical resection per standard of care and undergo near infrared (NIR) imaging with standard of care device.

    Treatment: Near Infrared Imaging, Therapeutic Conventional Surgery, and Tozuleristide

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Intraoperative Visualization of Oral Cavity Squamous Cell Carcinoma and High-Grade Dysplasia With Tozuleristide, a Fluorescent Tumor Marking Agent
Record updated
16 September 2026